Chris Bladen

Chris Bladen currently serves as the Acting Chief Executive Officer at Zymedyne Therapeutics since July 2021 and holds the position of Adjunct Assistant Professor at the University of Calgary, also starting in January 2023. In addition to these roles, Chris has been a Research Fellow and Lecturer at Macquarie University since July 2017, focusing on developing targeted therapies based on cannabinoid derivatives for conditions like epilepsy and pain. Chris has extensive experience as an Environmental Consultant with CEDA International, where responsibilities include Tailings Technology Analysis and ensuring compliance with environmental regulations. Previously, Chris worked as an Electrophysiology Consultant and has a strong background in the field, highlighted by a PhD in Neuroscience from the University of Calgary and over 20 published papers. Career history includes roles at various esteemed organizations, with a commitment to advancing research and regulatory practices in both neuroscience and environmental sectors.